{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sacubitril-Valsartan&page=2", "query": { "intervention": "Sacubitril-Valsartan", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 63, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sacubitril-Valsartan&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sacubitril-Valsartan&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T18:31:02.986Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01922089", "title": "Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Heart Failure With Reduced Ejection Fraction" ], "interventions": [ { "name": "LCZ696", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 498, "start_date": "2013-11", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2015-10-15", "last_synced_at": "2026-10-05T18:31:02.986Z", "location_count": 22, "location_summary": "Anchorage, Alaska • Gilbert, Arizona • Tucson, Arizona + 18 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01922089" }, { "nct_id": "NCT03938389", "title": "The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "PreDiabetes", "Impaired Glucose Tolerance", "Obesity", "Blood Pressure" ], "interventions": [ { "name": "Sacubitril-Valsartan Tab 97-103 MG", "type": "DRUG" }, { "name": "Valsartan 160mg", "type": "DRUG" }, { "name": "Placebo Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 90, "start_date": "2020-02-25", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2025-08-11", "last_synced_at": "2026-10-05T18:31:02.986Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03938389" }, { "nct_id": "NCT05279742", "title": "Enhancing the Natriuretic Peptide System in HFpEF", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Heart Failure With Preserved Ejection Fraction", "Chronic Kidney Diseases" ], "interventions": [ { "name": "MANP", "type": "DRUG" }, { "name": "Sacubitril/Valsartan", "type": "DRUG" }, { "name": "Oral Placebo", "type": "DRUG" }, { "name": "Injection Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Horng Chen", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2022-11-04", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2025-10-09", "last_synced_at": "2026-10-05T18:31:02.986Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05279742" }, { "nct_id": "NCT00887588", "title": "LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Heart Failure" ], "interventions": [ { "name": "LCZ696", "type": "DRUG" }, { "name": "Valsartan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 307, "start_date": "2009-11", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2015-08-25", "last_synced_at": "2026-10-05T18:31:02.986Z", "location_count": 11, "location_summary": "Little Rock, Arkansas • Chicago, Illinois • Detroit, Michigan + 8 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Grand Island", "state": "Nebraska" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00887588" }, { "nct_id": "NCT02226120", "title": "Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Heart Failure With Reduced Ejection Fraction" ], "interventions": [ { "name": "LCZ696", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1980, "start_date": "2014-10-16", "completion_date": "2017-12-28", "has_results": true, "last_update_posted_date": "2019-02-20", "last_synced_at": "2026-10-05T18:31:02.986Z", "location_count": 24, "location_summary": "Huntsville, Alabama • Muscle Shoals, Alabama • Little Rock, Arkansas + 20 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Oceanside", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02226120" }, { "nct_id": "NCT02636283", "title": "Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral Arterial Disease" ], "interventions": [ { "name": "Entresto", "type": "DRUG" }, { "name": "Placebo group", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 6, "start_date": "2017-12-31", "completion_date": "2018-11-01", "has_results": true, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-10-05T18:31:02.986Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02636283" }, { "nct_id": "NCT01920711", "title": "Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Failure With Preserved Ejection Fraction" ], "interventions": [ { "name": "LCZ696", "type": "DRUG" }, { "name": "Valsartan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 4822, "start_date": "2014-07-18", "completion_date": "2019-06-07", "has_results": true, "last_update_posted_date": "2020-09-29", "last_synced_at": "2026-10-05T18:31:02.986Z", "location_count": 110, "location_summary": "Huntsville, Alabama • Mobile, Alabama • Muscle Shoals, Alabama + 92 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01920711" }, { "nct_id": "NCT03066804", "title": "A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Failure With Preserved Ejection Fraction" ], "interventions": [ { "name": "sacubitril/valsartan", "type": "DRUG" }, { "name": "Enalapril", "type": "DRUG" }, { "name": "Valsartan", "type": "DRUG" }, { "name": "Placebo to match sacubitril/valsartan", "type": "DRUG" }, { "name": "Placebo to match enalapril", "type": "DRUG" }, { "name": "Placebo to match valsartan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": null, "sex": "ALL", "summary": "45 Years and older" }, "enrollment_count": 2572, "start_date": "2017-08-22", "completion_date": "2019-10-28", "has_results": true, "last_update_posted_date": "2021-10-11", "last_synced_at": "2026-10-05T18:31:02.986Z", "location_count": 32, "location_summary": "Andalusia, Alabama • Mobile, Alabama • Beverly Hills, California + 29 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Santa Ana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03066804" }, { "nct_id": "NCT04736433", "title": "Replication of the PARADIGM-HF Heart Failure Trial in Healthcare Claims Data.", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "ACE inhibitor", "type": "DRUG" }, { "name": "Sacubitril/Valsartan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6066, "start_date": "2020-09-22", "completion_date": "2021-02-18", "has_results": false, "last_update_posted_date": "2023-08-01", "last_synced_at": "2026-10-05T18:31:02.986Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04736433" }, { "nct_id": "NCT00549770", "title": "Efficacy and Safety of LCZ696A in Patients With Essential Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "LCZ696", "type": "DRUG" }, { "name": "Valsartan", "type": "DRUG" }, { "name": "AHU377", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1334, "start_date": "2007-09", "completion_date": "2008-07", "has_results": true, "last_update_posted_date": "2015-08-25", "last_synced_at": "2026-10-05T18:31:02.986Z", "location_count": 38, "location_summary": "Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Buena Park", "state": "California" }, { "city": "Fair Oaks", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00549770" } ] }